New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
08:00 EDTAEGRAegerion subpoena not a 'major surprise,' says Leerink
Leerink views the Aegerion's subpoena from the U.S. Department of Justice as not a "major surprise" after the FDA reprimanded the company for statements made by its CEO on CNBC that suggested Juxtapid can improve patient survival, which has not been studied in clinical trial. The firm expects the subpoena will result in more rigorous marketing practices controlled by compliance and a “manageable fine" and reiterates an Outperform rating on Aegerion.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
10:01 EDTAEGROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:15 EDTAEGROn The Fly: Pre-market Movers
Subscribe for More Information
08:36 EDTAEGRAegerion downgraded to Sell with $9 target at Guggenheim
Subscribe for More Information
06:11 EDTAEGRAegerion downgraded to Sell from Neutral at Guggenheim
Subscribe for More Information
June 25, 2015
07:34 EDTAEGRAegerion appoints Eleven Biotherapeutics CFO Gregory Perry as CFO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use